Healthcare provider profile · identity verified

Michael Eugene Campolo, DO

Family Practice · NEWARK, OH · NPI 1184604167

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	384	141
Levothyroxine Sodium	Levothyroxine Sodium	383	115
Omeprazole	Omeprazole	318	99
Amlodipine Besylate	Amlodipine Besylate	257	98
Metformin Hcl	Metformin Hcl	234	97
Simvastatin	Simvastatin	227	68
Losartan Potassium	Losartan Potassium	221	93
Rosuvastatin Calcium	Rosuvastatin Calcium	219	92
Lisinopril	Lisinopril	205	83
Metoprolol Succinate	Metoprolol Succinate	161	61
Pantoprazole Sodium	Pantoprazole Sodium	147	58
Metoprolol Tartrate	Metoprolol Tartrate	134	45
Hydrochlorothiazide	Hydrochlorothiazide	125	53
Glimepiride	Glimepiride	116	43
Potassium Chloride	Potassium Chloride	111	40
Furosemide	Furosemide	104	35
Allopurinol	Allopurinol	92	33
Tamsulosin Hcl	Tamsulosin Hcl	92	37
Trazodone Hcl	Trazodone Hcl	92	37
Gabapentin	Gabapentin	90	33
Alendronate Sodium	Alendronate Sodium	83	27
Sertraline Hcl	Sertraline Hcl	80	24
Fenofibrate	Fenofibrate	69	22
Buspirone Hcl	Buspirone Hcl	68	19
Montelukast Sodium	Montelukast Sodium	65	26
Escitalopram Oxalate	Escitalopram Oxalate	62	29
Oxybutynin Chloride Er	Oxybutynin Chloride	61	18
Eliquis	Apixaban	60	21
Pioglitazone Hcl	Pioglitazone Hcl	59	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	58	26
Carvedilol	Carvedilol	57	22
Fluoxetine Hcl	Fluoxetine Hcl	55	13
Citalopram Hbr	Citalopram Hydrobromide	54	23
Risperidone	Risperidone	54	suppressed
Benztropine Mesylate	Benztropine Mesylate	52	suppressed
Ezetimibe	Ezetimibe	51	22
Quetiapine Fumarate	Quetiapine Fumarate	47	suppressed
Fluticasone Propionate	Fluticasone Propionate	46	13
Duloxetine Hcl	Duloxetine Hcl	45	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	15
Ropinirole Hcl	Ropinirole Hcl	43	18
Meloxicam	Meloxicam	42	15
Synthroid	Levothyroxine Sodium	42	14
Warfarin Sodium	Warfarin Sodium	42	suppressed
Januvia	Sitagliptin Phosphate	41	12
Famotidine	Famotidine	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	38	20
Tramadol Hcl	Tramadol Hcl	37	16
Clopidogrel	Clopidogrel Bisulfate	36	15
Xarelto	Rivaroxaban	36	suppressed
Lovastatin	Lovastatin	35	11
Topiramate	Topiramate	35	suppressed
Donepezil Hcl	Donepezil Hcl	34	suppressed
Gemfibrozil	Gemfibrozil	34	suppressed
Fenofibrate	Fenofibrate,micronized	33	suppressed
Atenolol	Atenolol	32	15
Ozempic	Semaglutide	32	suppressed
Bupropion Hcl Sr	Bupropion Hcl	31	11
Lamotrigine	Lamotrigine	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	15
Trulicity	Dulaglutide	27	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	13
Clonazepam	Clonazepam	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Azithromycin	Azithromycin	24	16
Cilostazol	Cilostazol	24	suppressed
Finasteride	Finasteride	24	suppressed
Guanfacine Hcl	Guanfacine Hcl	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Clonidine Hcl	Clonidine Hcl	23	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	12
Spironolactone	Spironolactone	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	16
Oxcarbazepine	Oxcarbazepine	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Baclofen	Baclofen	18	suppressed
Prednisone	Prednisone	18	suppressed
Valsartan	Valsartan	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	15	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Minocycline Hcl	Minocycline Hcl	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Forteo	Teriparatide	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error